{"id":40980,"date":"2025-09-09T13:47:23","date_gmt":"2025-09-09T05:47:23","guid":{"rendered":"https:\/\/flcube.com\/?p=40980"},"modified":"2025-09-09T13:47:24","modified_gmt":"2025-09-09T05:47:24","slug":"remegen-secures-china-cde-approval-for-telitacicept-in-sjogrens-syndrome-first-biologic-of-its-kind","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40980","title":{"rendered":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind"},"content":{"rendered":"\n<p>China\u2011based pharmaceutical company <strong>RemeGen (<a href=\"https:\/\/www.google.com\/finance\/quote\/9995:HKG\">HKG: 9995<\/a>)<\/strong> announced that the <strong>Center for Drug Evaluation (CDE)<\/strong> of the National Medical Products Administration (NMPA) has accepted its new indication application for <strong>telitacicept<\/strong> (brand name: <em>Tacicept<\/em>) in the treatment of <strong>Sj\u00f6gren\u2019s syndrome<\/strong>. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-telitacicept\">About Telitacicept<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 A recombinant fusion protein that simultaneously targets <strong>B\u2011lymphocyte stimulator (BLyS)<\/strong> and <strong>proliferating\u2011inducing ligand (APRIL)<\/strong>, effectively dampening pathogenic B\u2011cell activity.<\/li>\n\n\n\n<li><strong>Prior Approvals<\/strong> \u2013 Already authorized in China for <strong>systemic lupus erythematosus (SLE)<\/strong>, <strong>rheumatoid arthritis (RA)<\/strong>, and <strong>generalized myasthenia gravis (gMG)<\/strong>.<\/li>\n\n\n\n<li><strong>Clinical Evidence<\/strong> \u2013 The Phase\u202f3, multicenter, randomized, double\u2011blind, placebo\u2011controlled study in Sj\u00f6gren\u2019s syndrome met all primary endpoints, showing sustained symptom improvement and a favorable safety profile.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-implications-for-the-autoimmune-market\">Implications for the Autoimmune Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011Mover Advantage<\/strong> \u2013 By becoming the first biologic approved for Sj\u00f6gren\u2019s syndrome, RemeGen positions itself at the forefront of a niche yet growing therapeutic area.<\/li>\n\n\n\n<li><strong>Global Expansion<\/strong> \u2013 The CDE clearance paves the way for parallel submissions in the EU, U.S., and other key markets, potentially unlocking multi\u2011billion\u2011dollar revenue streams.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong> \u2013 Current treatment options for Sj\u00f6gren\u2019s are limited to symptomatic care; telitacicept offers a targeted, disease\u2011modifying approach that could redefine standard of care.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-next-steps\">Next Steps<\/h3>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Regulatory Filings<\/strong> \u2013 RemeGen will prepare dossiers for the U.S. FDA, EMA, and other jurisdictions in the coming year.<\/li>\n\n\n\n<li><strong>Commercial Roll\u2011out<\/strong> \u2013 Pricing and reimbursement strategies will be tailored to each market, leveraging the drug\u2019s unique mechanism and robust data.<\/li>\n\n\n\n<li><strong>Post\u2011Marketing Studies<\/strong> \u2013 Ongoing safety surveillance and real\u2011world evidence collection will be critical to sustain payer confidence and market uptake.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40981,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1155,38,375],"class_list":["post-40980","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-9995","tag-market-approval-filings","tag-remegen"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its new indication application for telitacicept (brand name: Tacicept) in the treatment of Sj\u00f6gren\u2019s syndrome. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40980\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind\" \/>\n<meta property=\"og:description\" content=\"China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its new indication application for telitacicept (brand name: Tacicept) in the treatment of Sj\u00f6gren\u2019s syndrome. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40980\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T05:47:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-09T05:47:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind\",\"datePublished\":\"2025-09-09T05:47:23+00:00\",\"dateModified\":\"2025-09-09T05:47:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980\"},\"wordCount\":303,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0906.webp\",\"keywords\":[\"HKG: 9995\",\"Market approval filings\",\"RemeGen\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40980#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40980\",\"name\":\"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0906.webp\",\"datePublished\":\"2025-09-09T05:47:23+00:00\",\"dateModified\":\"2025-09-09T05:47:24+00:00\",\"description\":\"China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its new indication application for telitacicept (brand name: Tacicept) in the treatment of Sj\u00f6gren\u2019s syndrome. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40980\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0906.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0906.webp\",\"width\":1080,\"height\":608,\"caption\":\"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40980#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its new indication application for telitacicept (brand name: Tacicept) in the treatment of Sj\u00f6gren\u2019s syndrome. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40980","og_locale":"en_US","og_type":"article","og_title":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind","og_description":"China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its new indication application for telitacicept (brand name: Tacicept) in the treatment of Sj\u00f6gren\u2019s syndrome. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.","og_url":"https:\/\/flcube.com\/?p=40980","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-09T05:47:23+00:00","article_modified_time":"2025-09-09T05:47:24+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40980#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40980"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind","datePublished":"2025-09-09T05:47:23+00:00","dateModified":"2025-09-09T05:47:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40980"},"wordCount":303,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp","keywords":["HKG: 9995","Market approval filings","RemeGen"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40980#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40980","url":"https:\/\/flcube.com\/?p=40980","name":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40980#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40980#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp","datePublished":"2025-09-09T05:47:23+00:00","dateModified":"2025-09-09T05:47:24+00:00","description":"China\u2011based pharmaceutical company RemeGen (HKG: 9995) announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its new indication application for telitacicept (brand name: Tacicept) in the treatment of Sj\u00f6gren\u2019s syndrome. This marks the first time a biologic drug has been approved for this rare autoimmune disorder in the world.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40980#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40980"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40980#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp","width":1080,"height":608,"caption":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40980#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RemeGen Secures China CDE Approval for Telitacicept in Sj\u00f6gren\u2019s Syndrome, First Biologic of Its Kind"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0906.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40980"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40980\/revisions"}],"predecessor-version":[{"id":40982,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40980\/revisions\/40982"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40981"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}